Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Notably we have characterized the
2024-05-06

Notably, we have characterized the mechanism of action of ALK in the context of our current understanding of NLRP3 activation [5]. Non-priming macrophages, including BMDMs, exhibit no or minimal activation of NLRP3 in response to ATP. In contrast, LPS priming of macrophages makes them highly suscept
-
Introduction Aldose reductase ALR is
2024-05-06

Introduction Aldose reductase (ALR2) is the first enzyme of the polyol pathway that catalyzes the reduction of glucose to sorbitol utilizing NADPH as a cofactor. The intracellular accumulation of sorbitol, due to increased aldose reductase activity at high blood glucose levels, such as those occurr
-
Although several studies indicate that ALDH protects the hea
2024-05-06

Although several studies indicate that ALDH2 protects the heart from injury and maladaptive remodeling (reviewed in [11], [12], [13]), accumulating evidence indicates that deficiency of the enzyme could be protective as well. For example, mice expressing the defective Aldh2*2 mutation show lower ald
-
Further evidence for ACh GABA cotransmission
2024-05-03

Further evidence for ACh/GABA cotransmission had also been observed in the cortex. Extensive axonal arborization from cholinergic BF neurons exists throughout the cortical layers, allowing direct observation of cholinergic synaptic terminals. One study in the visual cortex of cat examined immunolabe
-
During the year study period of men
2024-05-03

During the 4-year study period, 19.9% of men in the dutasteride group developed prostate cancer as compared to 25.1% in the placebo group, which represents an absolute risk Firefly Luciferase mRNA synthesis of 5.1% for men taking dutasteride (Pe weighed against the prospect of undesirable sexual si
-
Physiology genetics and biochemistry of CYP A br
2024-05-03

Physiology, genetics, and sphingosine 1-phosphate receptor modulator of CYP17A1 Clinical presentation and diagnosis Treatment Acknowledgements I thank Dr. Hwei-Ming Peng for assistance with preparing Fig. 3. This work was supported by grant R01GM086596 from the National Institutes of Heal
-
Placental cells also express P aromatase CYP
2024-05-03

Placental cells also express P450 aromatase (CYP19A1, encoded by CYP19A1). In the placenta, this enzyme requires an external source of androgens, provided by the adrenal gland of the fetus, to form estrogen. The fetal adrenal gland produces dehydroepiandrosterone (DHEA) [9] and, in the placenta, it
-
Since immunoassays cannot specifically quantify each apelin
2024-05-03

Since immunoassays cannot specifically quantify each apelin peptide, a more reliable approach, mass spectrometry (MS) has been used recently to quantify and characterize apelin fragments in plasma. Using this technology, Zhen et al. showed that [Pyr-1]-apelin-13 was the major apelin form present in
-
G007-LK To further address the mechanism of
2024-05-03

To further address the mechanism of Didox’s suppressive effects on mast cell activation, FceRI receptor G007-LK and downstream transcription factor induction were assessed. We found that Didox had no effect on FceRI surface expression, and thus concluded that Didox effects must be occurring downstre
-
To circumvent these issues multiple approaches
2024-05-03

To circumvent these issues, multiple approaches have been developed that target small fractions of the genome, thus reducing the sequencing burden (Dostie et al., 2006; Fullwood et al., 2009; Mumbach et al., 2016). Application of one such approach, chromosome conformation capture carbon copy (5C), w
-
A previous review article suggested different washout interv
2024-05-03

A previous review article suggested different washout intervals based on specific clinical contexts [4]. While no consensus was reached for the optimal interval between last dose of BV and surgery for CRLM, the authors of the review suggested waiting 6 to 8 weeks after BV before surgery, particularl
-
What are the in situ effects of multi
2024-05-03

What are the in-situ effects of multi-site CaM associations with AT1R? Kai et al. showed that synthetic peptides corresponding to residues 125–137 (rat sequence) in SMD2, 217–227 in the N-terminal side of SMD3, and 304–316 in SMD4JM inhibit to various degrees AngII-induced GTPase activity of isolate
-
The only psychostimulant treatment option in
2024-05-02

The only psychostimulant treatment option in Turkey is methylphenidate (Çetin et al., 2015). It is broken down by carboxylase enzyme (CES1) (Sun et al., 2004). From the point of pharmacokinetics, it may be suggested that CES1 gene polymorphisms may be the key responsible factors in patients resistan
-
Nutlin3a australia Finally one can ask whether these results
2024-04-30

Finally, one can ask whether these results throw any light on the nature of the target in SNMG patients. Interestingly, the results of the in vitro incubations suggested that SNMG sera might increase AChR expression to a small extent, raising the possibility that SNMG patients, who have thymic chang
-
br Conclusion br Conflicts of Interest Disclosures br Acknow
2024-04-30

Conclusion Conflicts of Interest/Disclosures Acknowledgement This study was funded by the Ministry of Science of the Republic of Serbia (grant #175083). Introduction Myasthenia gravis (MG) is an antibody-mediated, neuromuscular transmission disorder, where the targets are postsynaptic p
16047 records 169/1070 page Previous Next First page 上5页 166167168169170 下5页 Last page